Polyclonal immunoglobulins (IVIg) induce expression of MMP-9 in microglia

Journal of Neuroimmunology

Volumn 217, Issue 1-2, 2009, Pages 46-50

  Pul, R ^a   Kopadze, T ^b   Skripuletz, T ^a   Voss, E V ^a   Kieseier, B C ^b   Stangel, M ^a,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Center for Systems Neurosciences Hanover   (Germany)

Author keywords

Intravenous immunoglobulins; IVIg; Matrix metalloproteinase; Microglia; MMP 9

Indexed keywords

GELATINASE A; GELATINASE B; IMMUNOGLOBULIN 7S; IMMUNOGLOBULIN F(AB) FRAGMENT; LIPOPOLYSACCHARIDE; MACROPHAGE ELASTASE; MATRILYSIN; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; UNCLASSIFIED DRUG; VENIMMUN N;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME RELEASE; ENZYME SYNTHESIS; IMMUNE RESPONSE; IMMUNOMODULATION; MICROGLIA; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BRAIN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 9; MICROGLIA; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70449658833     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.09.016     Document Type: Article

References (53)

1. Agrawal S., Anderson P., Durbeej M., van Rooijen N., Ivars F., Opdenakker G., and Sorokin L.M. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 4 (2006) 1007-1019
2. Alby C., Ben Abdesselam O., Foglietti M.J., and Beaudeux J.L. Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood. Clin. Chim. Acta 1-2 (2002) 183-186
3. Anthony D.C., Ferguson B., Matyzak M.K., Miller K.M., Esiri M.M., and Perry V.H. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol. Appl. Neurobiol. 5 (1997) 406-415
4. Anthony R.M., Wermeling F., Karlsson M.C., and Ravetch J.V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. U. S. A 50 (2008) 19571-19578
5. Barro C., Zaoui P., Morel F., and Benhamou P.Y. Matrix metalloproteinase expression in rat pancreatic islets. Pancreas 4 (1998) 378-382
6. Chandler S., Coates R., Gearing A., Lury J., Wells G., and Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci. Lett. 3 (1995) 223-226
7. Chang C.J., Hsu L.A., Ko Y.H., Chen P.L., Chuang Y.T., Lin C.Y., Liao C.H., and Pang J.H. Thrombin regulates matrix metalloproteinase-9 expression in human monocytes. Biochem. Biophys. Res. Commun. 2 (2009) 241-246
8. Cossins J.A., Clements J.M., Ford J., Miller K.M., Pigott R., Vos W., Van D.V., and De Groot C.J. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol. 6 (1997) 590-598
9. Cuzner M.L., Gveric D., Strand C., Loughlin A.J., Paemen L., Opdenakker G., and Newcombe J. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 12 (1996) 1194-1204
10. Dehmel T., Janke A., Hartung H.P., Goebel H.H., Wiendl H., and Kieseier B.C. The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies. Neurobiol. Dis. 3 (2007) 665-674
11. Dubois B., Masure S., Hurtenbach U., Paemen L., Heremans H., van den O.J., Sciot R., Meinhardt T., Hammerling G., Opdenakker G., and Arnold B. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J. Clin. Invest 11 (1999) 1507-1515
12. Esparza J., Kruse M., Lee J., Michaud M., and Madri J.A. MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity. FASEB J. 14 (2004) 1682-1691
13. Gerlach R.F., Demacq C., Jung K., and Tanus-Santos J.E. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin. Biochem. 1-2 (2007) 119-123
14. Gijbels K., Proost P., Masure S., Carton H., Billiau A., and Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J. Neurosci. Res. 4 (1993) 432-440
15. Giulian D., and Baker T.J. Characterization of ameboid microglia isolated from developing mammalian brain. J. Neurosci. 8 (1986) 2163-2178
16. Gottschall P.E. beta-Amyloid induction of gelatinase B secretion in cultured microglia: inhibition by dexamethasone and indomethacin. NeuroReport 18 (1996) 3077-3080
17. Gottschall P.E., and Deb S. Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation. 2-3 (1996) 69-75
18. Gottschall P.E., Yu X., and Bing B. Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture. J. Neurosci. Res. 3 (1995) 335-342
19. Hartung H.P., and Kieseier B.C. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol. 2 (2000) 140-147
20. Humle J.S., and Sorensen P.S. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. J. Neurol. Sci. 1-2 (2005) 61-65
21. Hurnaus S., Mueller-Felber W., Pongratz D., and Schoser B.G. Serum levels of matrix metalloproteinases-2 and -9 and their tissue inhibitors in inflammatory neuromuscular disorders. Eur. Neurol. 4 (2006) 204-208
22. Jack C., Ruffini F., Bar-Or A., and Antel J.P. Microglia and multiple sclerosis. J. Neurosci. Res. 3 (2005) 363-373
23. Jorgensen S.H., Storm N., Jensen P.E., Laursen H., and Sorensen P.S. IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions. Exp. Brain Res. 4 (2007) 462-469
24. Jung K., Lein M., Laube C., and Lichtinghagen R. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin. Chim. Acta 1-2 (2001) 241-244
25. Kuhlmann T., Wendling U., Nolte C., Zipp F., Maruschak B., Stadelmann C., Siebert H., and Bruck W. Differential regulation of myelin phagocytosis by macrophages/microglia, involvement of target myelin, Fc receptors and activation by intravenous immunoglobulins. J. Neurosci. Res. 2 (2002) 185-190
26. Larsen P.H., and Yong V.W. The expression of matrix metalloproteinase-12 by oligodendrocytes regulates their maturation and morphological differentiation. J. Neurosci. 35 (2004) 7597-7603
27. Larsen P.H., Wells J.E., Stallcup W.B., Opdenakker G., and Yong V.W. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J. Neurosci. 35 (2003) 11127-11135
28. Larsen P.H., DaSilva A.G., Conant K., and Yong V.W. Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. J. Neurosci. 8 (2006) 2207-2214
29. Lassmann H. New concepts on progressive multiple sclerosis. Curr. Neurol. Neurosci. Rep. 3 (2007) 239-244
30. Leppert D., Waubant E., Burk M.R., Oksenberg J.R., and Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 6 (1996) 846-852
31. Liuzzi G.M., Santacroce M.P., Peumans W.J., Van Damme E.J., Dubois B., Opdenakker G., and Riccio P. Regulation of gelatinases in microglia and astrocyte cell cultures by plant lectins. Glia 1 (1999) 53-61
32. Liuzzi G.M., Latronico T., Fasano A., Carlone G., and Riccio P. Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult. Scler. 3 (2004) 290-297
33. Liuzzi G.M., Latronico T., Rossano R., Viggiani S., Fasano A., and Riccio P. Inhibitory effect of polyunsaturated fatty acids on MMP-9 release from microglial cells-implications for complementary multiple sclerosis treatment. Neurochem. Res. 12 (2007) 2184-2193
34. Mannello F., Tanus-Santos J.E., Meschiari C.A., and Tonti G.A. Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices. Anal. Biochem. 1 (2008) 56-63
35. Mayer A.M., Hall M., Fay M.J., Lamar P., Pearson C., Prozialeck W.C., Lehmann V.K., Jacobson P.B., Romanic A.M., Uz T., and Manev H. Effect of a short-term in vitro exposure to the marine toxin domoic acid on viability, tumor necrosis factor-alpha, matrix metalloproteinase-9 and superoxide anion release by rat neonatal microglia. BMC. Pharmacol. 7 (2001)
36. Nimmerjahn F., and Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 1 (2008) 34-47
37. Nuttall R.K., Silva C., Hader W., Bar-Or A., Patel K.D., Edwards D.R., and Yong V.W. Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia. Glia 5 (2007) 516-526
38. Oh L.Y., Larsen P.H., Krekoski C.A., Edwards D.R., Donovan F., Werb Z., and Yong V.W. Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J. Neurosci. 19 (1999) 8464-8475
39. Proost P., Van Damme J., and Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem. Biophys. Res. Commun. 3 (1993) 1175-1181
40. Pul R., Nguyen D., Schmitz U., Marx P., and Stangel M. Comparison of intravenous immunoglobulin preparations on microglial function in vitro: more potent immunomodulatory capacity of an IgM/IgA-enriched preparation. Clin. Neuropharmacol. 5 (2002) 254-259
41. Rosenberg G.A. Matrix metalloproteinases in neuroinflammation. Glia 3 (2002) 279-291
42. Rosenberg G.A. Matrix metalloproteinases biomarkers in multiple sclerosis. Lancet 9467 (2005) 1291-1293
43. Shapiro S., Shoenfeld Y., Gilburd B., Sobel E., and Lahat N. Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer 9 (2002) 2032-2037
44. Sorensen P.S., Haas J., Sellebjerg F., Olsson T., and Ravnborg M. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 11 (2004) 2028-2033
45. Stangel M., and Compston A. Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors. J. Neuroimmunol. 1-2 (2001) 63-71
46. Stangel M., Joly E., Scolding N.J., and Compston D.A. Normal polyclonal immunoglobulins ('IVIg') inhibit microglial phagocytosis in vitro. J. Neuroimmunol. 1-2 (2000) 137-144
47. Tanuma N., Sakuma H., Sasaki A., and Matsumoto Y. Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol. 2 (2006) 195-204
48. Uhm J.H., Dooley N.P., Oh L.Y., and Yong V.W. Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia 1 (1998) 53-63
49. van Horssen J., Vos C.M., Admiraal L., van Haastert E.S., Montagne L., Van D.V., and de Vries H.E. Matrix metalloproteinase-19 is highly expressed in active multiple sclerosis lesions. Neuropathol. Appl. Neurobiol. 6 (2006) 585-593
50. Visser L.H., Beekman R., Tijssen C.C., Uitdehaag B.M., Lee M.L., Movig K.L., and Lenderink A.W. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult. Scler. 1 (2004) 89-91
51. Warrington A.E., Asakura K., Bieber A.J., Ciric B., Van K.V., Kaveri S.V., Kyle R.A., Pease L.R., and Rodriguez M. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A 12 (2000) 6820-6825
52. Wells G.M., Catlin G., Cossins J.A., Mangan M., Ward G.A., Miller K.M., and Clements J.M. Quantitation of matrix metalloproteinases in cultured rat astrocytes using the polymerase chain reaction with a multi-competitor cDNA standard. Glia 4 (1996) 332-340
53. Yong V.W. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat. Rev. Neurosci. 12 (2005) 931-944